The nitric oxide-donating pravastatin derivative, NCX 6550 [(1S-[1α(βS*, δS*), 2α, 6α, 8β-(R*), 8aα]]-1,2,6,7,8,8a-hexahydro-β, δ, 6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-naphtalene-heptanoic acid 4-(nitrooxy)butyl ester)], reduces splenocyte adhesion and reactive oxygen species generation in normal and atherosclerotic mice by Dever, G. et al.
JPET #109298 
 1
Title:  The NO-donating pravastatin derivative (NCX 6550) reduces Splenocyte 
Adhesion and ROS Generation in Normal and Atherosclerotic Mice 
 
 
Dever G, Spickett CM, Kennedy S, Rush C, Tennant G, Monopoli A & Wainwright CL 
 
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 
Glasgow, Scotland UK (GD, CMS, SK, CR, GT).  School of Pharmacy, The Robert 
Gordon University, Aberdeen, Scotland UK (CLW). Nicox Research Institute, Milan, 
Italy (AM) 
 
 JPET Fast Forward. Published on September 27, 2006 as DOI:10.1124/jpet.106.109298
 Copyright 2006 by the American Society for Pharmacology and Experimental Therapeutics.
This article has not been copyedited and formatted. The final version may differ from this v rsion.
JPET Fast Forward. Published on September 27, 2006 as DOI: 10.1124/jpet.106.109298
 at A
SPET Journals on D
ecem
ber 21, 2018
jpet.aspetjournals.org
D
ow
nloaded from
 
JPET #109298 
2 
Running title: NO-releasing pravastatin and splenocyte adhesion
 
 
Author for Correspondence 
Professor Cherry L Wainwright  
School of Pharmacy 
The Robert Gordon University 
Schoolhill 
Aberdeen AB10 1FR 
Scotland UK 
Tel: 01224 262450 
Fax:  01224 262555 
E-mail: c.wainwright@rgu.ac.uk 
Document Statistics 
Number of text pages:  27 
Number of Tables: 0 
Number of Figures: 6 
Number of References: 40 
Abstract: 250 
 
Introduction: 768 
 
Discussion: 1542 
 
Abbreviations: 
APES - 3-aminopropyl triethoxysilane; ApoE-/- - Apolipoprotein E receptor knockout; 
CL – chemiluminescence; ICAM-1 – inter-cellular adhesion molecule 1; MCP-1 – 
monocyte chemoattractant protein 1; MPO – myeloperoxidase; NADPH oxidase – 
nicotinamide adenine dinucleotide phosphate-H; NCX 6550 – Nitrated pravastatin ((1S-
[1α(βS*,δS*),2α,6α,8β-(R*),8aα]]-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-
(2-methyl-1-oxobutoxy)-1-naphtaleneheptanoic acid 4-(nitrooxy)butyl ester); NO – nitric 
oxide; NOX - NOX-based NAD(P)H oxidases; PAR-1 – protease activated receptor 1; 
PHOX – phagocyte oxidase; PMA – phorbol myristate acetate; ROS – reactive oxygen 
species; SOD – superoxide dismutase; VCAM-1 – vascular cell adhesion molecule 1 
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on September 27, 2006 as DOI: 10.1124/jpet.106.109298
 at A
SPET Journals on D
ecem
ber 21, 2018
jpet.aspetjournals.org
D
ow
nloaded from
 
JPET #109298 
 3
 Abstract
 
Statins possess anti-inflammatory effects that may contribute to their ability to slow 
atherogenesis while nitric oxide (NO) also influences inflammatory cell adhesion.  This 
study aimed to determine whether a novel NO-donating pravastatin derivative, NCX 
6550, has greater anti-inflammatory properties compared to pravastatin in normal and 
atherosclerotic ApoE -/- mice.  C57Bl/6 and ApoE -/- mice were administered pravastatin 
(40 mg/kg), NCX 6550 (48.5 mg/kg) or vehicle orally for 5 days.  Ex vivo studies 
assessed splenocyte adhesion to arterial segments and splenocyte ROS generation.  NCX 
6550 significantly reduced splenocyte adhesion to artery segments in both C57Bl/6 (8.8 ± 
1.9 vs 16.6 ± 6.7 % adhesion; P<0.05) and ApoE -/- mice (9.3 ± 2.9 vs 23.4 ± 4.6 % 
adhesion; P<0.05) concomitant with an inhibition of endothelial ICAM-1 expression.  
NCX 6550 also significantly reduced PMA-induced ROS production that was enhanced 
in isolated ApoE -/- splenocytes. Conversely, pravastatin had no significant effects on 
adhesion in normal or ApoE -/- mice, but reduced the enhanced ROS production from 
ApoE -/- splenocytes.  In separate groups of ApoE -/- mice, NCX 6550 significantly 
enhanced endothelium-dependent relaxation to carbachol in aortic segments 
precontracted with phenylephrine (-logEC50 6.37 ± 0.37) compared to both vehicle (-
logEC50 5.81 ± 0.15; P<0.001) and pravastatin (-log EC50 5.57 ± 0.45; P<0.05) treated 
mice.  NCX 6550 also significantly reduced plasma MCP-1 levels (648.8 pg/ml) 
compared to both vehicle (1191.1 pg/ml; P<0.001) and pravastatin (847±71.0 pg/ml; 
P<0.05) treatment.  These data show that NCX 6550 exerts superior anti-inflammatory 
actions compared to pravastatin, possibly through NO-related mechanisms.     
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Introduction 
Atherosclerosis is now generally acknowledged to be an inflammatory disease where 
inflammation develops at certain predilection sites in response to endothelial injury.  
Attachment of leukocytes to atherosclerotic blood vessels (Ramos et al., 1999), coupled 
with upregulation of the vascular adhesion molecules VCAM-1 and ICAM-1 (Nakashima 
et al., 1998) is a fundamental step in the development of atherosclerosis.  Recently, 
adhesion of cultured murine monocytoid WEH1 78/24 cells to artery segments of ApoE -
/- mice has been demonstrated (Li et al., 2005) supporting the notion that a hyper-
inflammatory state exists in developing atherosclerosis.  This has been attributed to 
increased levels of a number of cytokines, which act to elevate adhesion molecule 
expression.  Thrombin, in addition to playing a role in the coagulation cascade, is also 
involved in the regulation of inflammation and has been shown to induce monocyte 
adhesion to endothelial cells (HUVEC) through induction of ICAM-1 and increased 
expression of VCAM-1, P-selectin and E-selectin (Kaplanski et al., 1998) due to an 
action at PAR-1.  Consequently, thrombin has been implicated in atherogenesis 
(Coughlin, 2005).  However, there has been no direct demonstration of a hyper-
inflammatory response to thrombin in atherosclerotic blood vessels.  The first aim of the 
current study was therefore to compare adhesion of splenocyte preparations, commonly 
used as a source of immune cells, to thrombin-challenged arterial tissue from normal 
(C57Bl/6) and atherosclerotic (ApoE -/-) mice. 
 
The value of introducing the lipid-lowering statins into the management of patients with 
coronary artery disease has been illustrated through the significant benefit of these drugs 
in primary (Shepherd et al., 1995) and secondary prevention of symptomatic coronary 
heart disease (Scandinavian Simvastatin Survival Study (4S), 1994). Detailed analyses of 
data from these trials, however, suggest that lipid-lowering by statins does not solely 
account for the significant clinical outcomes, and that statins possess additional 
(pleiotropic) effects beyond their lipid-lowering capacity (Downs et al., 1998).  Among 
the reported pleiotropic effects of statins, demonstrations of their anti-inflammatory and 
anti-adhesive effects are abundant (Fischetti et al., 2004; Sparrow et al., 2001; Stalker et 
al., 2001).  Furthermore fluvastatin (Bandoh et al, 2003), and other statins, have been 
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shown to inhibit formation of reactive oxygen species (ROS) by inflammatory cells.  
However, while these effects are readily demonstrated following acute challenge with 
supratherapeutic concentrations in vitro, the effects in vivo often require prolonged 
administration before they are observed.  Although nitric oxide (NO) was originally 
identified as a key mediator in the maintenance of vascular tone it also exerts anti-
inflammatory effects.  NO, either generated endogenously or released from NO-donating 
molecules, inhibits leukocyte adhesion through a reduction in endothelial expression of 
adhesion molecules such as P-selectin (Davenpeck et al., 1994) and ICAM-1 (Berendji-
Grun et al., 2001).  Recent studies have reported superior anti-inflammatory properties of 
novel NO–releasing statins (nitrostatins), over the respective native statins in RAW 264.7 
murine macrophage cells (Ongini et al., 2004; Rossiello et al., 2005).  The NO-donating 
moiety of nitrostatins is similar to other nitro compounds such as nitro aspirin, which 
yields NO through metabolic hydrolysis resulting in relatively long lasting plasma levels 
of NO (Muscara et al, 2001).  Furthermore, studies conducted with the NO-releasing 
derivative of pravastatin, NCX 6550 ((1S-[1α(βS*,δS*),2α,6α,8β-(R*),8aα]]-
1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-1-
naphtalene -heptanoic acid 4-(nitrooxy)butyl ester)), showed that the compound given 
to hypercholesterolemic CD1 mice is equally effective as equivalent doses of the native 
statin at lowering cholesterol (Monopoli et al, Personal Communication).  Thus, NO 
released by these molecules may provide a more rapid anti-inflammatory action than can 
be achieved with a native statin, while still affording a reduction in cholesterol levels.  
Thus the aim of the present study was to compare the effects of short-term (5 days) in 
vivo administration of NCX 6550 and native pravastatin on ex vivo splenocyte adhesion 
to arterial segments, splenocyte ROS production, and endothelial ICAM-1 expression in 
tissues from normal (C57Bl/6) and atherosclerotic (ApoE -/-) mice.  In addition we 
determined the effects of these interventions on endothelium-dependent vasorelaxant 
function and plasma MCP-1 levels in ApoE -/- mice. 
 
While many studies that investigated leukocyte-endothelial adhesion have used in vitro 
cell models, such as myeloid cell adhesion to HUVEC monolayers (McGettrick et al, 
2006), we chose to use a more physiological model involving in vivo dosing with statins 
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followed by ex vivo measurement of isolated splenocyte adhesion to arterial tissue.  
Although this approach has the limitation of being a static model of vascular adhesion, it 
has the advantage of allowing atherosclerosis-susceptible arteries to be studied, in 
contrast to intravital microscopy, which is a dynamic model that allows the detection of 
adhesion in the presence of shear stress, but which involves visualising microvascular 
beds that are not generally susceptible to atherosclerotic plaque development, such as the 
mesenteric bed.   
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Methods
 
 
Materials 
C57Bl/6 (Harlan, UK Ltd) and ApoE -/- (Charles River Laboratories, France) mice were 
bred in house at the University of Strathclyde. NCX 6550 (1S-[1α(βS*,δS*),2α,6α,8β-
(R*),8aα]]-1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-
1-naphtaleneheptanoic acid 4-(nitrooxy)butyl ester) was synthesised at NicOx (Bresso, 
Milan, Italy). All chemicals were purchased from Sigma-Aldrich, unless otherwise stated. 
 
Experimental Design 
Forty C57Bl/6 (18-24 g) and fifty  two ApoE -/- (26-35 g) age matched mice of either sex 
were employed in the study, under a project licence issued under the UK Animals 
(Scientific Procedures) Act 1986.  The ApoE -/- mice were fed on an atherogenic diet 
(1% cholesterol, 5% lard) for 12 weeks post-weaning, and control normocholesterolaemic 
C57Bl/6 mice were fed normal laboratory chow.  The mice were then employed for the 
following studies: 
(1)  A group of C57Bl/6 (n=10) and ApoE -/- (n=10) mice were used in preliminary 
experiments to determine any difference between the strains with respect to the adhesive 
response to thrombin, ICAM-1 expression and splenocyte ROS generation.  
(2)  Three groups (n=10 per group) of mice of each strain were administered either 
vehicle (DMSO: Castor oil: PEG 400: Water, 1: 2: 7: 10 v/v/v/v), native pravastatin (40 
mg/kg) or NCX 6550 (equimolar dose, 48.5 mg/kg) by oral gavage every day (at 10 a.m.) 
for 5 days.  One hour after the final dose the mice were euthanised by CO2 asphyxiation.  
Heparinised blood was obtained by cardiac puncture immediately following euthanasia 
for subsequent measurement of plasma cholesterol levels using standard assay kits (R-
Biopharm). 
(3)  Three groups (n=4 per group) of ApoE -/- were administered either vehicle, 
pravastatin or NCX6550 (all as above) for 5 days.  Immediately following euthanasia 
blood was collected by cardiac puncture into heparinised tubes for measurement of 
plasma MCP-1 using an ELISA assay kit (Insight Bioscience, UK) and the aorta 
harvested for determination of blood vessel function. 
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Splenocyte Isolation and Radiolabelling  
Splenocyte suspensions were prepared by disrupting the spleens over a 200 µm mesh 
(Cadisch Ltd) into 3 mL of RPMI-1640 medium (Dutch Modification: Invitrogen Ltd, 
UK) containing 10% foetal calf serum (Invitrogen).  The resulting cell suspensions were 
passed through a 200 µm mesh and centrifuged at 125 g for 10 min.  The supernatants 
were removed, the pellets containing the cells agitated with 4 mL of distilled H2O for 30 
seconds (to lyse erythrocytes), followed by addition of 4 mL 1.8% NaCl to restore 
isotonicity.  The splenocyte suspensions were filtered through a 200µm mesh, centrifuged 
and the resulting cell pellets re-suspended in 2 mL of RPMI.  Cell density was 
determined using a haemocytometer, and the suspension diluted as necessary to achieve a 
final density of 1x106 cells Ll-1.  1ml of the re-suspended leukocytes was labelled for 1hr 
at 37°C in a humidified chamber with 185 kBq of 51Cr (Amersham Biosciences, UK); the 
cells were agitated every 15 min to minimise cell sedimentation.  The cells were washed 
twice with RPMI and re-suspended in RPMI to 1x106 cells mL-1. 
 
Splenocyte Characterisation 
Splenocyte preparations were characterised in samples from three separate C57Bl/6 and 
three ApoE -/- mice using flow cytometry.  Briefly, cell suspensions were incubated with 
FcR blocking buffer (anti-CD 16/32 hybridoma supernatant, 10% mouse serum and 0.1% 
azide) for 5 min to prevent binding of antibody to cells via Fc regions.  The cell 
suspensions were then incubated with a mixture of cell lineage specific antibodies for 40 
min at 4°C.  B lymphocytes were identified using flourescein isothiocynate (FITC) 
conjugated anti-CD45R/B220 (clone RA3-6B2; Pharmingen, Oxford, UK), CD4+ T 
lymphocytes using Peridinin chlorophyll protein-cyanin 5.5 (PerCP) conjugated anti-CD4 
(clone GK1.5; BD Pharmingen, Oxford, UK) and myeloid cells using Phycoerythrin (PE) 
conjugated anti-CD11b (clone M1/70; BD Pharmingen, Oxford, UK).  The cells were 
washed in FACS buffer (PBS, 2% FCS and 0.1% azide) prior to acquisition using a BD 
FACSCanto flow cytometer with FACSDiVa software (BD, UK).  FlowJo software (Tree 
Star Inc, USA) was used for three colour analysis.  To ascertain which cell types were 
adhering to the artery surface, cells were added to pinned out segments of aorta for 30 
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minutes and adherent cells were harvested by addition of ice cold PBS solution.  The 
suspensions of adherent cells were incubated with the same three antibodies and run 
through the flow cytometer. 
 
Assessment of Splenocyte Adhesion to Aortic Segments 
The method employed was a modification of a method utilising rabbit tissue developed in 
our laboratory to determine the effects of vascular injury on inflammatory cell adhesion 
(Kennedy et al., 2000).  Homologous aortic lengths were removed and cut into two 
segments (aortic arch and thoracic aorta), which were pinned out luminal-side up onto 
Sylgard blocks (Dow Corning, Germany).  The artery segments were incubated with 10µl 
of 10 U mL-1 thrombin for 10 min in a humidified chamber (37°C), washed and then 
incubated with a 5 µL aliquot of the labelled leukocytes for a further 30 min.  The 
segments were then washed with RPMI, transferred into microtubes and assayed for 51Cr 
in a gamma counter (Cobra™ Auto-gamma®, Packard, Canberra Company, UK).  
Aliquots (5 µL) of labelled and unlabelled cells were also counted to allow calculation of 
leukocyte adhesion using the following equation: 
(1)  % Adhesion = (γartery – background)/(γsplenocytes – background) x 100 
where γartery = count from the artery and γsplenocytes =  count from a 5 µL aliquot of labelled 
splenocytes. 
 
Measurement of Splenocyte ROS Generation 
A 450 µL aliquot of unlabelled splenocyte suspension (1x106 cells mL-1) was diluted 1:1 
with phosphate-buffered saline (PBS) in a plastic cuvette containing a stir bar, which was 
then placed in the pre-warming chamber of a chemiluminometer (Chronolog 
Corporation) for 2 min.  100 µL of 400 µg mL-1 luminol (5-amino-2,3-dihydro-1,4-
phthalazinedione) were added prior to the cuvette being transferred to the photomultiplier 
compartment.  After 1 min the cells were stimulated with 5-100 ng mL-1 (final 
concentrations) of phorbol myristate acetate (PMA), and a cumulative chemiluminescent 
signal was measured for 15 min. 
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Immunocytochemistry 
Upon completion of the adhesion assay, artery segments were fixed in formalin solution 
(4% formaldehyde) for 48 h and stored in PBS at 4°C.  The tissues were subsequently 
processed and embedded in blocks of paraffin wax.  4 µm transverse sections were cut 
and mounted on APES-treated slides and oven-dried for 1hr at 60°C.  Sections were then 
stained for ICAM-1 with goat anti-human/anti-mouse ICAM-1 as the primary polyclonal 
antibody (1:50; R&D Systems, UK) and biotinylated rabbit anti-goat secondary antibody 
(1:400; Dako, USA) using the streptavidin-horse radish peroxidase (Vector, UK) method 
as described previously in detail (Kennedy et al., 2000).  The sections were then 
counterstained with haematoxylin prior to mounting in DPX (VWR International).  
Sections were subsequently subjected to semi-quantitative scoring analysis by one of us 
(CW) blinded to the treatment.  Sections were scored from 0-3, where 0= 
none/background; 0.5= focal staining of the endothelium; 1= mild circumferential 
positivity on the endothelium; 2= moderate circumferential positivity on the endothelium; 
3= intense circumferential positivity on the endothelium.  
 
Assessment of endothelial function 
Endothelial function was measured using a small artery wire myograph (Danish Myo 
Technology, Aarhus, Denmark). Briefly, 2mm segments of thoracic aorta were mounted 
on two 40µm stainless steel wires and normalised using a previously published method. 
Arteries were bathed in Krebs’ solution, maintained at 37ºC and aerated with 95% O2 and 
5% CO2 throughout. Following 30 mins of equilibration, all arteries were constricted by 
addition of a previously determined EC50 of phenylephrine (0.2 µM).  Once contraction 
had stabilised, endothelium-dependent relaxation was measured by cumulative addition 
of carbachol (10-9 M–10-4 M).  Maximum relaxation (Emax) and -logEC50 for each group 
of mice was calculated by fitting sigmoidal curves to each complete data set using 
GraphPad Prism version 4 (GraphPad Software Inc.). 
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Measurement of Plasma MCP-1 Levels 
Plasma MCP-1 levels were measured using a mouse CCL2 ELISA kit (Insight 
Bioscience, Wembley, UK).  Briefly, NUNC Maxisorp flat-bottom, high protein binding 
capacity 96-well plates were coated overnight at 4°C with 100 µL / well purified anti-
mouse MCP-1 capture antibody (1:250 in coating buffer [Insight Bioscience]), after 
which they were aspirated and washed 3 times with 300 µL / well wash buffer (0.05% 
Tween-20 in PBS).  Non-specific binding was blocked by incubation with 200 µL / well 
assay diluent (10% foetal bovine serum in PBS) for 1 hour at room temperature, the wells 
washed and standards (0-2000 pg mL-1 recombinant mouse MCP-1) and plasma samples 
(100 µL / well) added.  The plate was then incubated at room temperature for 2 hours, 
aspirated  and washed and 100 µL / well detection antibody (1:250 in assay buffer) added 
followed by incubation at room temperature for 1 hour.   After a further aspiration and 
wash, 100 µL of Avidin-HRP (1:250 in assay buffer) was added to each well and the 
plate was incubated at room temperature for 30 min, after which each plate was subjected 
to seven cycles of aspirate and wash.  100 µL of 60 µg mL-1 TMB (tetramethylbenzidine) 
substrate solution was added to each well; the plate incubated at room temperature for 15 
min, and the reaction stopped by addition of 50 µL / well of stop solution (1 M H3PO4).  
The plate was read on a SpectraMax 190 plate reader (Molecular Devices Corporation, 
Sunnyvale, California): MCP-1 levels were determined by subtracting the absorbance 
values at 570 nm from those at 450 nm and extrapolating values from the standard curve. 
 
 
Statistics 
Values shown are mean ± s.e.m.  Multiple group comparisons for % splenocyte adhesion, 
ROS generation, plasma cholesterol and MCP-1 levels and immunostaining scores were 
performed using One-way ANOVA and Dunnett’s Post-Hoc test.  For the functional 
studies, complete dose response curves were compared by Two-Way ANOVA, while 
Emax and –logEC50 values were compared by One-way ANOVA and Tukey post-hoc test. 
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Results
 
Characterisation of splenocyte preparations 
Splenocytes isolated from the C57Bl/6 mice all contained similar proportions of CD4+ T 
lymphocytes, B-220+ B lymphocytes and CD11b+ myeloid cells.  Together these 
accounted for approximately 80% of the cell population.  Analysis of the cell types 
adhering after 30 minutes contact with arterial segments revealed that all three cell types 
were present in approximately the same proportion as was found in the splenocyte 
isolates (Figure 1).  In ApoE-/- mice both the isolated splenocytes and the adherent cells 
exhibited a greater proportion of B lymphocytes than in the C57Bl/6 mice, although the 
proportion of CD4+ T lymphocytes and CD11b+ myeloid cells were similar in both strians 
(Figure 1).  The remaining 10-20% of cells in both strains were most likely CD8+ and γδ+ 
T lymphocytes. 
 
Influence of atherosclerosis on adhesive response to thrombin 
In a preliminary series of experiments performed in a separate group of mice that did not 
receive any form of oral drug administration, a significant difference was observed in the 
adhesive response to thrombin in both the aortic arch and the thoracic aorta from ApoE -
/- mice compared to normal mice (Figure 2A).  Furthermore, splenocytes isolated from 
ApoE -/- mice generated substantially more ROS on challenge with PMA than 
splenocytes from C57Bl/6 mice (Figure 2B).   
 
Thrombin-stimulated splenocyte adhesion and ICAM-1 expression 
Figure 3A illustrates splenocyte adhesion to arterial segments from vehicle- and drug-
treated C57Bl/6 mice following five days of pre-treatment.  Native pravastatin had no 
effect, whereas NCX 6550 caused a reduction in splenocyte adhesion which, in the aortic 
and thoracic segments, was statistically significant compared to both the vehicle and 
pravastatin groups (P<0.05).  NCX 6550 also inhibited adhesion in the thoracic segment 
in the ApoE -/- mice, whereas pravastatin did not (Figure 3B); no significant reduction in 
adhesion to the aortic segment with NCX6550 was observed, presumably due to the 
greater variability within this group (P=0.17) .  There was no significant difference in the 
extent of ICAM-1 expression in thrombin-treated artery segments from vehicle controls 
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for either strain of mouse (Figure 4).  NCX 6550 significantly reduced the extent of 
ICAM-1 staining observed in the segments from C57Bl/6 and ApoE -/- groups compared 
to vehicle-treated mice.  Pravastatin, on the other hand, only reduced ICAM-1 expression 
in thrombin-treated segments from C57Bl/6 mice and not the ApoE -/- mice. 
 
Splenocyte Reactive Oxygen Species Generation 
Treatment with pravastatin had no effect on the extent of ROS generation from C57Bl/6 
splenocytes, whereas NCX 6550 significantly reduced ROS generation in response to the 
highest concentration of PMA tested (Figure 5A).  In contrast, both pravastatin and NCX 
6550 significantly attenuated the enhanced ROS production in the ApoE -/- splenocytes 
to a similar degree (Figure 5B). 
 
Endothelial Function 
Treatment with NCX 6550 significantly enhanced endothelium-dependent relaxation in 
response to carbachol (Figure 6A) in ApoE -/- mice by causing a significant shift to the 
left of the dose response curve (EC50 0.43 ± 0.37 µM compared to 1.55 ± 0.15 µM  in 
vehicle treated mice; P<0.05) and an increase in Emax (67.55 ± 9.4% relaxation) compared 
to vehicle treated mice (Emax 39.1 ± 3.6%; P<0.05).  Pravastatin did not cause any shift in 
the dose response curve (EC50 2.73 ± 0.45 µM), but the maximum relaxant response was 
increased (Emax 63.4 ± 16.9%; P<0.05 compared to vehicle). 
 
Plasma MCP-1 
Both pravastatin and NCX 6550 reduced circulating MCP-1 levels (847.2 ± 71.0 pgmL-1, 
P<0.01 and 648.8 ± 47.4 pgmL-1, P<0.001 respectively) compared to vehicle control 
(1191.1 ± 176.1 pgmL-1).  MCP-1 levels in NCX 6550 treated mice were significantly 
(P<0.05) lower than levels measured in mice treated with pravastatin. 
 
Plasma Cholesterol Levels 
Plasma cholesterol levels in vehicle–treated ApoE -/- mice (1835 ± 345 µg mL-1) were 
significantly higher (P<0.01) than in vehicle-treated C57Bl/6 mice (550 ± 83µg mL-1).  
Plasma cholesterol levels were not affected by 5 day treatment with either pravastatin 
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(428 ± 153 and 2526 ± 350 µg mL-1 in C57Bl/6 and ApoE -/-, respectively) or NCX 6550 
(305 ± 47 and 1628 ± 392 µg mL-1 in C57Bl/6 and ApoE -/-, respectively).
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Discussion
 
Hypercholesterolaemia increases thrombin-stimulated splenocyte adhesion and ROS 
generation 
In the present study we have shown that in vitro thrombin-induced adhesion of 
splenocytes to autologous arterial segments is enhanced in ApoE -/- mice compared to 
wild type controls.  Although there was a higher proportion of B lymphocytes in the 
splenocyte preparations from ApoE -/- mice (51.4 ± 0.5% of the total cell population) 
compared to C57Bl/6 mice (33.6 ± 4.2%), our finding that for each strain the adherent 
cell populations were made up of similar ratios of these three cell types implies that the 
increased adhesion is not due to the increased B lymphocyte adhesion alone.  Regarding 
the molecular basis of this enhanced adhesion, ICAM-1 is known to play a key role in 
firm adhesion of monocytes and lymphocytes in response to thrombin (Nie et al., 1997).  
However, our immunocytochemical determination of ICAM-1 expression does not 
support the notion that increased ICAM-1 expression is responsible for the increased 
adhesion in ApoE -/- arteries, although ROS-induced increases in binding affinity of 
ICAM-1 (Sellak et al., 1994) may play a role.  Alternatively, we have found that 
expression of the thrombin receptor PAR-1 is increased in arteries from ApoE -/- mice 
(Pugh et al., unpublished), which might explain the enhanced response to thrombin.    
 
Blood vessels from atherosclerotic animals (Stokes et al., 2002) and humans with 
coronary artery disease (Spiekermann et al., 2003) generate elevated levels of ROS.  Our 
observation that splenocytes from ApoE -/- mice similarly generate substantially greater 
amounts of ROS is, to our knowledge, the first demonstration of this phenomenon, 
although the relative contribution of each cell type in the splenocyte suspensions to the 
total CL signal is unknown. Elevated ROS generation from leukocytes has been 
described in obese (Dandona et al., 2001) and Type II diabetic (Orie et al., 2000) patients, 
but data from patients with atherosclerosis is conflicting (Eid et al., 2002; Araujo et al., 
1995).  ROS generation by monocytes and neutrophils in disease models is well 
established, but evidence is now mounting that T-lymphocytes also generate ROS 
(Williams & Kwon, 2004), for example by the lipoxygenase pathway (Los et al., 1995), 
mitochondrial electron transport chain (Griendling et al., 2000) or NOXs (Lambeth, 
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2004), although there is no information regarding the effect of hypercholesterolaemia on 
these systems.  The present use of luminol as a chemiluminescent probe measures total 
ROS production by the splenocyte preparations, which precludes determining whether 
the enhanced CL signal from ApoE -/- splenocytes is due to overproduction of 
superoxide or other ROS species.  We have found previously (Lim et al., 2006) that a 
combination of SOD, catalase and sodium azide cannot completely inhibit CL generated 
by mouse splenocytes, implying that superoxide, hydrogen peroxide and 
myeloperoxidase products do not account for all the ROS generated and that other ROS 
(such as hydroxyl radical, singlet oxygen, lipid peroxide and nitric oxide) may also 
contribute to the CL signal.   
 
The NO-donating pravastatin derivative (NCX 6550), but not pravastatin, inhibits 
thrombin-induced splenocyte adhesion in ApoE -/- mice 
The key finding of this study was that NCX 6550 significantly reduced splenocyte 
adhesion to arterial tissue from both normocholesterolaemic and hypercholesterolaemic 
mice and inhibited ICAM-1 expression in arterial segments challenged with thrombin.  In 
contrast, native pravastatin did not attenuate thrombin-stimulated adhesion, although it 
did reduce the expression of ICAM-1 in C57Bl/6, but not in ApoE -/- mice.  This 
apparent dissociation between an anti-adhesive response and inhibition of ICAM-1 
expression supports the findings in untreated animals.  The failure of pravastatin to 
inhibit splenocyte adhesion ex vivo deviates from the growing body of evidence that 
statins, including pravastatin, exert some of their effects through anti-inflammatory 
mechanisms that are unrelated to lipid lowering (Schonbeck & Libby, 2004).  However, 
most studies that demonstrate an anti-inflammatory effect of statins employed treatment 
periods longer than the 5-day period in the present study, suggesting that long-term 
treatment is required to observe an anti-inflammatory effect.  For example, 2 and 4 weeks 
treatment with rosuvastatin was required to attenuate adhesion of a monocyte cell line to 
aortic segments and vascular ROS production in ApoE -/- mice (Li et al., 2005).  
Interestingly, in that study cholesterol levels were reduced by rosuvastatin, whereas in the 
present study no observable effects of either pravastatin or NCX 6550 were detected 
(presumably due to the different duration of drug treatment).  Moreover, most in vitro 
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studies demonstrating an anti-inflammatory effect of statins have employed 
concentrations in the micromolar range, whereas in vivo data suggest that plasma 
concentrations in the nanomolar range may have an effect on leukocyte trafficking and 
recruitment.  This has led to the notion that cell adhesion and migration in vivo, which is 
a dynamic environment, may be more sensitive to inhibition by statins than adhesion 
under static in vitro conditions.  Although in the present study pravastatin was 
administered in vivo, the adhesion measurements were performed ex vivo under static 
conditions, which could explain the lack of effect of pravastatin. 
 
The superior ability of NCX 6550 over native pravastatin, to reduce splenocyte adhesion 
ex vivo, to improve endothelial function and to reduce MCP-1 levels suggests that it is the 
NO moiety on this compound that is responsible for its anti-adhesive effect.  Using 
spectroscopy to measure nitrosylhaemoglobin in rat whole blood, Ongini et al. (2004) 
have demonstrated a linear, time-dependent increase in NO release from NCX 6550 that 
was consistent with slow NO release kinetics.  The quantity of NO released was 
suggested to parallel that produced by eNOS under physiological conditions.  The 
increase in local NO levels resulting from NCX 6550 treatment could result in an anti-
inflammatory effect since NO is known to interfere with the release of a number of 
inflammatory mediators (such as caveolin-1 and NFκB) and the expression of adhesion 
molecules (Guzik et al., 2003).  An alternative explanation for the superior effect of NCX 
6550, however, could be attributed to a physicochemical, rather than a pharmacological 
difference between the two compounds, since pravastatin is known to be weakly effective 
in vitro because of its low lipophilicity, while the different physicochemical properties of 
NCX 6550 make it more lipophilic and consequently increase its penetration into cells 
(Ongini et al., 2004).   
 
Both NCX6550 and pravastatin inhibit splenocyte ROS production 
In contrast to the findings with splenocyte adhesion and ICAM-1 expression, both 
pravastatin and NCX 6550 attenuated the increase in ROS generation from ApoE -/- 
splenocytes.  As would be expected after such a short period of administration (5 days) 
neither drug reduced plasma cholesterol and therefore this effect is unlikely to be 
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mediated through a lipid lowering effect.  However, this shared property does imply that 
it is an effect mediated through the statin molecule.  It has been demonstrated that statins 
can reduce ROS generation from vascular tissue by reducing levels of p22phox mRNA 
(Wassmann et al., 2001) and can act directly as ROS scavengers (Bandoh et al., 2003).  
The present novel finding that statins can also inhibit ROS generation from inflammatory 
cells that are intimately involved in atherogenesis and plaque rupture offers a further 
mechanism by which these compounds exert their highly beneficial effect.  Interestingly, 
NCX 6550 also reduced ROS generation in response to the highest concentration of PMA 
tested in splenocytes from normocholesterolaemic mice.  This action may be related to 
the NO moiety, since we have previously shown that NO-donating drugs can scavenge 
ROS generated by inflammatory cells (Demiryurek et al., 1997). 
 
NCX 6550 and pravastatin on endothelial function  
Among the proposed pleiotropic effects of statins is an improvement in endothelial 
function through an increased bioavailability of nitric oxide, a reduction in oxidative 
stress and the promotion of re-endothelialization (Wolfrum et al., 2003).  Our present 
studies support this notion through the demonstration that pravastatin increased the 
maximum response to carbachol.  However, under the same conditions, treatment with 
NCX 6550 exerted a superior effect on endothelial function by increasing the sensitivity 
to an endothelium–dependent vasodilator (as demonstrated by the left-ward shift in EC50) 
as well as increasing maximum response.  This is consistent with previous observations 
that NCX 6550 improves endothelial function in hypertensive rats (Presotto et al., 2005), 
and is likely due to the enhanced NO availability provided by the molecule. 
 
NCX 6550 and pravastatin on MCP-1 levels 
MCP-1 is known to mediate monocyte recruitment into vessel walls at sites of 
atherosclerosis and raised MCP-1 levels have been associated with cardiovascular disease 
risk factors.  The reduction in MCP-1 levels seen here with pravastatin is consistent with 
numerous studies demonstrating the ability of statins to reduce MCP-1 (reviewed in 
Ballantyne and Nambi, 2005).  As with the effect on endothelial function, NCX 6550 had 
a greater influence on MCP-1 levels than native pravastatin.  The ability of NO to 
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on September 27, 2006 as DOI: 10.1124/jpet.106.109298
 at A
SPET Journals on D
ecem
ber 21, 2018
jpet.aspetjournals.org
D
ow
nloaded from
 
JPET #109298 
 19
modulate MCP-1 expression in endothelial cells is well documented (Zeiher et al., 1995) 
and it is therefore reasonable to propose that the enhanced activity of NCX 6550 is due to 
the presence of the NO-donating moiety. 
 
Conclusions 
Taken together, our findings suggest that NCX 6550, which retains the properties of the 
parent statin compound while having the added asset of slow nitric oxide release, is 
significantly more effective than native pravastatin in relation to several inflammatory 
markers.  Clinically this may be important in terms of maintaining plaque stability and 
endothelial function that is compromised by raised circulating cholesterol levels, and the 
provision of these beneficial effects early on in drug treatment (i.e. within days rather 
than months) certainly warrants further investigation. 
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Figure Legends 
Figure 1:  Percentage of T-lymphocytes, B-lymphocytes and myeloid cells present in 
mouse spleen cell isolates (panel A) and in populations of cells adhering to aortic 
segments following 30 mins incubation (panel B). Cell type was determined by flow 
cytometry using 3 colour analysis in cell preparations from C57Bl/6 and ApoE -/- mice, 
either directly using the splenocyte preparation or after adherence to artery segments and 
subsequent release using ice-cold PBS.  CD4+ T lymphocytes were identified using  
PerCP-conjugated anti-CD4; B lymphocytes were identified using FITC-conjugated anti-
CD45R/B220; myeloid cells were identified by Phycoerythrin-conjugated anti-CD11b.  
The results are shown as mean ± s.e.m. (n=3).   *P<0.05 compared to C57Bl/6 in both 
panels. 
 
Figure 2:
  Thrombin-stimulated splenocyte adhesion to aortic and thoracic arterial 
segments from ApoE -/- and C57Bl/6 mice  (panel A).  Arterial segments were treated 
with thrombin for 10 mins prior to incubation with 51Cr-labelled splenocytes for 30 mins 
at 37oC. Adhesion is expressed as a percentage of the total cells applied to the artery 
segment and results correspond to mean ± s.e.m. (n=10 for both groups).  The generation 
of ROS from isolated splenocytes in response to PMA was measured using luminol-
dependent chemiluminescence (panel B). Results are shown as mean ± s.e.m. (n = 6 for 
wild type controls and 10 for ApoE -/-).  *P<0.05 compared to C57Bl/6 in both panels. 
  
Figure 3:
  The effect of NCX 6550 and pravastatin administration on adhesion of 
isolated splenocytes to thrombin-treated artery segments from both wild type (panel A) 
and ApoE -/- (panel B) mice. Percent adhesion refers to the percentage of cells applied to 
the vessel segment that remained adherent after washing, which was determined as 
described for figure 2A. The results are presented as mean ± s.e.m. with n=11 for wild 
type and n=13 for ApoE -/- mice. *P<0.05 compared to vehicle-treated controls. 
 
Figure 4:
  Immunocytochemical staining scores (arbitrary scale) for ICAM-1 in 
thrombin-treated arterial segments from C57Bl/6 and ApoE -/- mice treated with vehicle, 
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pravastatin or NCX 6550.  *P<0.05; **P<0.01; ***P<0.001 compared to vehicle treated 
control mice (n=6 per group).  Details of the scoring system are described in the 
Methods. 
 
Figure 5:  The effect of NCX 6550 and pravastatin administration on ROS production 
from C57Bl/6 splenocytes (panel A) and ApoE -/- splenocytes (panel B). ROS production 
was measured as described for figure 2B. Data are presented as mean ± s.e.m (n=4-6 per 
group); *P<0.05; **P<0.01 compared to vehicle control. 
 
Figure 6:  The effect of NCX 6550 and pravastatin administration on endothelial 
function in isolated aortic segments from ApoE -/- mice. Endothelial relaxant response 
was assessed by wire myography, with pre-constriction induced by 0.2 µM phenylephrine 
and relaxation by cumulative addition of carbachol.  The results were analysed using 
Prism graph plotting software to calculate Emax and -logEC50, and are shown as mean ± 
s.e.m (n=4). *P<0.05 (NCX vs pravastatin)  ***P<0.001 (NCX vs vehicle) (Two-way 
ANOVA).   
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